Biogen Stock News

Boston Trust Walden Corp acquired a new position in Biogen Inc. (NASDAQ:BIIB) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 714 shares of the biotechnology company’s stock, valued at approximately $202,000. Other institutional investors and hedge funds have also […]

Investors hope the combination of laggards will make one go-getter Related Stocks: ABBV , AMGN , BIIB , NSE:BIOCON , MRK , NVS , PFE , RHHBY , VTRS , SNY ,

Sumitomo Mitsui Trust Holdings Inc. reduced its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 5.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 465,619 shares of the biotechnology companys stock after selling 29,106 shares during the quarter. Sumitomo []

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) reached a new 52-week low during mid-day trading on Friday following insider selling activity. The stock traded as low as $7.75 and last traded at $7.76, with a volume of 66523 shares. The stock had previously closed at $8.14. Specifically, major shareholder Biogen Inc. sold 52,178 shares of the [] The post Sangamo Therapeutics (NASDAQ:SGMO) Sets New 12-Month Low Following Insider Selling appeared first on ETF Daily News .

Eudaimonia Partners LLC increased its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 30.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,829 shares of the biotechnology companys stock after buying an additional 430 shares during the period. Eudaimonia Partners []

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) major shareholder Biogen Inc. sold 52,178 shares of Sangamo Therapeutics stock in a transaction that occurred on Tuesday, December 7th. The shares were sold at an average price of $8.52, for a total transaction of $444,556.56. The transaction was disclosed in a filing with the SEC, which is available at this []

Related Stocks: FB , BIIB , LAMR , ZD , QRVO , BBY , BX , EXPD , EVRG , HSY , SBUX , MMM , LOW , PGR , DTE , KLAC , LRCX , CMCSA ,

Biogen Inc. (NASDAQ:BIIB) Analysts at Cantor Fitzgerald lifted their FY2022 earnings estimates for Biogen in a research report issued to clients and investors on Wednesday, December 8th. Cantor Fitzgerald analyst A. Young now expects that the biotechnology company will earn $16.57 per share for the year, up from their previous estimate of $16.49. Cantor []

WBUR''s All Things Considered host Lisa Mullins talks with STAT biotech reporter Damian Garde about the publication''s recent special report on problems at Cambridge-based Biogen.

Firm adds to holding in medical device manufacturer Check out PRIMECAP Management Stock Picks » Download GuruFolio Report of PRIMECAP Management (Updated on 12/09/2021) Related Stocks: LUNG , LLY , MSFT , BIIB , ADBE , TXN ,

DUBLIN--(BUSINESS WIRE)--The "Global Multiple Sclerosis Drugs Market 2020-2027" report has been added to ResearchAndMarkets.com''s offering. The global multiple sclerosis drugs market will reach $29.97 billion by 2027, growing by 4.3% annually over 2020-2027 owing to the growing prevalence of multiple sclerosis (MS), the rise in funding for multiple sclerosis research, and increasing approvals of novel MS drugs. The report is based on a comprehensive research of the entire global multiple sclero

Related Stocks: EQC , BIIB , NVTA ,

DUBLIN--(BUSINESS WIRE)--The "Global Spinal Muscular Atrophy Treatment Market (2021-2026) by Disease Type, Treatment, Route of Administration and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com''s offering. The Global Spinal Muscular Atrophy Treatment Market is estimated to be USD 1.1 Bn in 2021 and is expected to reach USD 1.98 Bn by 2026, growing at a CAGR of 12.5%. The SMA treatment market is growing at a signifi

DUBLIN--(BUSINESS WIRE)--The "Biosimilar Lymphocyte Modulator Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com''s offering. The global biosimilar lymphocyte modulator market is expected to grow from $1.22 billion in 2020 to $1.31 billion in 2021 at a compound annual growth rate (CAGR) of 7.4%. The market is expected to reach $1.91 billion in 2025 at a CAGR of 10%. Major players in the biosimilar lymphocyte modulator market are Pfizer,